IR and HR of composite serious infections in tocilizumab initiators vs TNFi, propensity score-matched with a 1:3 variable ratio
| Tocilizumab | TNFi | HR (95% CI) | Rate difference† | |||||||
| Subjects (n) | Events | Person-years | IR* (95% CI) | Subjects (n) | Events | Person-years | IR* (95% CI) | |||
| As-treated analysis | ||||||||||
| Medicare | 5827 | 341 | 4840 | 7.05 (6.30 to 7.79) | 10 716 | 662 | 9193 | 7.20 (6.65 to 7.75) | 0.94 (0.82 to 1.07) | −0.15 (−1.08, 0.78) |
| IMS | 4642 | 147 | 4130 | 3.56 (2.98 to 4.13) | 10 333 | 249 | 9860 | 2.53 (2.21 to 2.84) | 1.30 (1.05 to 1.61) | 1.03 (0.37, 1.69) |
| MarketScan | 5605 | 130 | 4228 | 3.07 (2.55 to 3.60) | 12 060 | 244 | 9897 | 2.47 (2.16 to 2.77) | 1.16 (0.93 to 1.44) | 0.60 (−0.01, 1.21) |
| Combined | 16 074 | 618 | 13 198 | 4.68 (4.31 to 5.05) | 33 109 | 1155 | 28 950 | 3.99 (3.76 to 4.22) | 1.05 (0.95 to 1.16) | 0.69 (0.25, 1.13) |
| Intention-to-treat analysis up to 180 days | ||||||||||
| Medicare | 5827 | 226 | 2638 | 8.57 (7.45 to 9.68) | 10 716 | 407 | 4815 | 8.45 (7.63 to 9.27) | 0.98 (0.83 to 1.16) | 0.12 (−1.27, 1.51) |
| IMS | 4642 | 91 | 2131 | 4.27 (3.39 to 5.15) | 10 333 | 150 | 4740 | 3.16 (2.66 to 3.67) | 1.22 (0.94 to 1.60) | 1.11 (0.1, 2.12) |
| MarketScan | 5605 | 83 | 2445 | 3.39 (2.66 to 4.13) | 12 060 | 136 | 5260 | 2.59 (2.15 to 3.02) | 1.26 (0.95 to 1.66) | 0.80 (−0.05, 1.65) |
| Combined | 16 074 | 400 | 7214 | 5.54 (5.00 to 6.09) | 33 109 | 693 | 14 815 | 4.68 (4.33 to 5.03) | 1.04 (0.91 to 1.20) | 0.86 (0.21, 1.51) |
*Incidence rate (IR) is per 100 person-years.
†Rate difference per 100 patients (tocilizumab-TNFi).
TNFi, tumour necrosis factor inhibitors.